Exhibit 99.1

 

LOGO    FOR IMMEDIATE RELEASE

American Vanguard Reports Full Year 2025 Results

Company Extends and Expands Its Credit Capacity Through the Establishment of Two Term Loans

Forecasts Adjusted EBITDA in a range of $44 - $48 million in 2026

Announces the Company will be rationalizing its Los Angeles manufacturing facility

Newport Beach, CA | March 16, 2026 — American Vanguard® Corporation, a diversified specialty and agricultural products company that develops, manufactures, and markets solutions for crop protection and nutrition, turf and ornamental management and commercial pest control, today reported financial results for the financial year ended December 31, 2025.

Financial and Operational Highlights for 2025 – versus 20241:

 

   

Net sales of $515 million vs. $547 million;

 

   

GAAP net loss of $50 million vs $126 million;

 

   

Adjusted EBITDA2 of $39.2 million vs. $39.1 million;

 

   

The Company has entered in two new term loans agreements totaling $285 million

Dak Kaye, CEO of American Vanguard, stated “2025 was a pivotal year for American Vanguard as we continue to make progress on the execution of our business improvement plans. Initiatives that we implemented early last year have resulted in increased margins, in an agricultural economy that is just beginning to recover. While we have accomplished much in 2025, we expect even better results in 2026. We have made the difficult decision to significantly reduce activities at the Company’s Los Angeles manufacturing facility. This is the Company’s oldest facility, and in today’s environment, is no longer competitive. We would like to thank our dedicated team members at this location. We will be assisting the affected employees as they transition to new opportunities. Further, savings will also be realized from the Company’s previously announced move of the corporate headquarters from Newport Beach, California, scheduled for mid-2026.”

Mr. Kaye continued, “We also have replaced our revolving credit facility with term loans from lenders led by Centerbridge Partners and BMO. This transaction meaningfully strengthens American Vanguard’s capital structure and liquidity position. This financing extends our maturities, enhances balance-sheet flexibility, and positions the Company to remain focused on executing its strategic and operational priorities. We now intend to position American Vanguard for growth, with a portfolio of new products that will begin launching this year.”

Mr. Kaye concluded, “The Company has also made personnel changes to the management of our commercial team, which I believe will reenergize this group. With new products and a renewed customer centric focus, there is an opportunity to meaningfully increase volumes, that will lead to improved efficiency in our factory operations, higher margins, and ultimately to higher future profitability. I expect the Company to generate adjusted EBITDA in a range of $44 - $48 million in 2026.”

 

 
1 

2024 GAAP figures include adjustments related to a product recall.

2 

Adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA) is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net (loss) income, operating (loss) income or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from adjusted EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company’s competitors) may define adjusted EBITDA differently.

 

1


David Johnson, Chief Financial Officer stated, “I am pleased to see our business improvement plans begin to yield tangible results. Our 2025 gross profit margin and operating costs both improved as compared to 2024. These results are important given the backdrop of a continued weak overall agricultural market. As planned, we continued to wind down spending on our business improvement action plans. In 2026, we will continue to invest in business improvements including rationalization of some activity at the LA facility, which will result in short term cash and non-cash expenses followed by longer term factory operating efficiencies. Finally, I am particularly pleased to be able to report that the Company has fully remediated all of the material weaknesses identified in connection with the 2024 audit. I want to thank the entire global finance team and many other non-finance employees who have all worked together to achieve this result”. 

Mr. Johnson continued, “As we look forward to 2026, I feel that a lot of work has been done to improve the Company’s organization, approach to new product introductions, operations and capital structure. Further, we will continue to focus on using technology to improve our business by completing the global implementation of our standard ERP platform. These actions will allow the Company to grow as the global Ag Chem market continues to improve.”

Earnings Conference Call

The Company will be hosting an earnings conference call at March 16, 2026 at 4:30 pm Eastern Time/1:30 pm Pacific Time.

The conference call can be accessed through the following link: https://www.webcaster5.com/Webcast/Page/3070/53740

A replay of this event can be accessed through the Company website.

The Company plans to post on the Investor Relations section of the Company’s website a supplemental presentation that should be read in connection with this earnings release.

About American Vanguard

American Vanguard Corporation is a diversified specialty and agriculture products company that develops and markets products for crop protection and management, turf and ornamentals management, and public and animal health. Over the past 20 years, through product and business acquisitions, the Company has significantly expanded its operations and now has more than 1,000 product registrations worldwide. To learn more about the Company, please reference www.american-vanguard.com.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release the matters set forth in this press release include forward-looking statements. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements often use words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project,” “outlook,” “forecast,” “target,” “trend,” “plan,” “goal,” or other words of comparable meaning or future-tense or conditional verbs such as “may,” “will,” “should,” “would,” or “could.” These forward-looking statements are based on the current expectations and estimates by the Company’s management and are subject to various risks and uncertainties that may cause results to differ from management’s current expectations. Such factors include risks detailed from time-to-time in the Company’s SEC reports and filings. All forward-looking statements, if any, in this release represent the Company’s judgment as of the date of this release. The Company disclaims any intent or obligation to update these forward-looking statements.

 

2


Non-GAAP Financial Measures    

In addition to providing results that are determined in accordance with accounting principles generally accepted in the United States of America (GAAP), we present Adjusted EBITDA, which is a non-GAAP financial measure. This measure should not be considered in isolation or as an alternative to GAAP measures such as net income, or diluted earnings per share, as applicable, or other financial statement data presented in our financial statements as an indicator of our financial performance or liquidity.

We define EBITDA as net income or net income attributable to the Company, adjusted for non-controlling interests, depreciation and amortization, provision for income taxes and interest expense. We define Adjusted EBITDA as EBITDA as further adjusted for certain items management believes are not reflective of the underlying operations of our business, including but not limited to the exclusion of charges that are considered by management to be unusual and not representative of the company’s underlying performance and future prospects. In 2025 and 2024 that included non-recurring expenses and the profit on sale of an asset that was not held for sale. The resulting Adjusted EBITDA measure is aligned with the Company’s metric for its credit facility agreement in the applicable periods.

We use Adjusted EBITDA to assess the operating results and effectiveness and efficiency of our business. We present this non-GAAP financial measure because we believe that investors consider Adjusted EBITDA to be an important supplemental measure of performance, and we believe that this measure is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. As the Company continues to work through its transformation efforts, management believes that presenting Adjusted EBITDA provides an effective comparison between the Company and its industry peers. Non-GAAP financial measures as reported by us may not be comparable to similarly titled metrics reported by other companies and may not be calculated in the same manner. These measures have limitations as analytical tools, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP.

The Company is not able to provide a reconciliation without unreasonable efforts of its forward-looking guidance related to adjusted EBITDA to the most directly comparable GAAP financial measure due to the inherent difficulty in predicting with reasonable certainty the timing and amount of certain items that are excluded from Adjusted EBITDA, such as share-based compensation, acquisition-related expenses, and foreign exchange gains or losses, which could be material to the Company’s results computed in accordance with GAAP.

 

3


Investor Representative

Alpha IR Group

Robert Winters

Robert.winters@alpha-ir.com

(929) 266-6315

 

4


CONSOLIDATED BALANCE SHEETS

December 31, 2025 and 2024

(In thousands, except share data)

 

     2025     2024  

Assets

    

Current assets:

    

Cash

   $ 12,425     $ 12,514  

Receivables:

    

Trade, net of allowance for credit losses of $11,733 and $9,190 respectively

     160,511       169,743  

Other

     7,278       4,699  
  

 

 

   

 

 

 

Total receivables, net

     167,789       174,442  
  

 

 

   

 

 

 

Inventories

     176,034       179,292  

Prepaid expenses and other assets

     9,668       7,615  

Income taxes receivable

     4,606       5,030  
  

 

 

   

 

 

 

Total current assets

     370,522       378,893  

Property, plant and equipment, net

     53,036       58,169  

Operating lease right-of-use assets, net

     16,793       19,735  

Intangible assets, net

     138,746       150,497  

Goodwill

     —        19,701  

Deferred income tax assets

     2,637       1,242  

Other assets

     14,803       8,484  
  

 

 

   

 

 

 

Total assets

   $ 596,537     $ 636,721  
  

 

 

   

 

 

 

Liabilities and Stockholders’ Equity

    

Current liabilities:

    

Accounts payable

   $ 87,505     $ 69,159  

Customer prepayments

     33,094       52,675  

Accrued program costs

     52,227       69,449  

Accrued expenses and other payables

     28,261       31,989  

Operating lease liabilities, current

     5,765       6,136  

Income taxes payable

     2,594       2,942  
  

 

 

   

 

 

 

Total current liabilities

     209,446       232,350  

Long-term debt

     174,000       147,332  

Operating lease liabilities, long-term

     11,621       14,339  

Deferred income tax liabilities

     8,150       7,989  

Other liabilities

     923       1,601  
  

 

 

   

 

 

 

Total liabilities

     404,140       403,611  
  

 

 

   

 

 

 

Commitments and contingent liabilities (Notes 5 and 10)

    

Stockholders’ equity:

    

Preferred stock, $0.10 par value per share; authorized 400,000 shares; none issued

     —        —   

Common stock, $0.10 par value per share; authorized 40,000,000 shares; issued 34,923,562 shares in 2025 and 34,794,548 shares in 2024

     3,492       3,479  

Additional paid-in capital

     117,106       114,679  

Accumulated other comprehensive loss

     (12,000     (18,729

Retained earnings

     155,000       204,882  
  

 

 

   

 

 

 
     263,598       304,311  

Less treasury stock at cost, 5,915,182 shares in 2025 and 5,915,182 in 2024

     (71,201     (71,201
  

 

 

   

 

 

 

Total stockholders’ equity

     192,397       233,110  
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 596,537     $ 636,721  
  

 

 

   

 

 

 

 

5


CONSOLIDATED STATEMENTS OF OPERATIONS

Years ended December 31, 2025, 2024 and 2023

(In thousands, except per share data)

 

     2025     2024     2023  

Net sales

   $ 515,114     $ 547,306     $ 579,371  

Cost of sales

     (367,553     (426,989     (400,207
  

 

 

   

 

 

   

 

 

 

Gross profit

     147,561       120,317       179,164  

Operating expenses

      

Selling, general and administrative

     (110,633     (119,634     (116,887

Research, product development and regulatory

     (23,161     (32,662     (38,025

Product liability claims

     (9,730     —        —   

Transformation

     (7,187     (20,162     (957

Asset impairments

     (25,395     (50,414     —   

Gain from sale of assets

     249       1,000       —   
  

 

 

   

 

 

   

 

 

 

Operating (loss) income

     (28,296     (101,555     23,295  

Change in fair value of equity investments, net

     (437     (2,356     (359

Interest and other expenses, net

     (18,470     (16,547     (12,639
  

 

 

   

 

 

   

 

 

 

(Loss) income before provision for income taxes

     (47,203     (120,458     10,297  

Provision for income taxes

     (2,679     (5,882     (2,778
  

 

 

   

 

 

   

 

 

 

Net (loss) income

   $ (49,882   $ (126,340   $ 7,519  
  

 

 

   

 

 

   

 

 

 

(Losses) earnings per common share—basic

   $ (1.75   $ (4.50   $ 0.27  
  

 

 

   

 

 

   

 

 

 

(Losses) earnings per common share—assuming dilution

   $ (1.75   $ (4.50   $ 0.26  
  

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding—basic

     28,426       28,059       28,128  
  

 

 

   

 

 

   

 

 

 

Weighted average shares outstanding—assuming dilution

     28,426       28,059       28,533  
  

 

 

   

 

 

   

 

 

 

 

6


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

ANALYSIS OF SALES

(In thousands)

 

     2025     2024     $ Change     % Change  

Net sales:

        

U.S. crop

   $ 221,391     $ 228,327     $ (6,936     -3

U.S. non-crop

     90,290       82,400       7,890       10
  

 

 

   

 

 

   

 

 

   

Total U.S.

     311,681       310,727       954       0

International

     203,433       236,579       (33,146     -14
  

 

 

   

 

 

   

 

 

   

Total net sales

   $ 515,114     $ 547,306     $ (32,192     -6

Total cost of sales

   $ (367,553   $ (426,989   $ 59,436       -14
  

 

 

   

 

 

   

 

 

   

Total gross profit

   $ 147,561     $ 120,317     $ 27,244       23
  

 

 

   

 

 

   

 

 

   

Total gross margin

     29     22    

 

7


CONSOLIDATED STATEMENTS OF CASH FLOWS

Years ended December 31, 2025, 2024 and 2023

(In thousands)

 

     2025     2024     2023  

Cash flows from operating activities:

      

Net (loss) income

   $ (49,882   $ (126,340   $ 7,519  

Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:

      

Depreciation and amortization of property, plant and equipment and intangible assets

     18,742       22,322       21,780  

Amortization of other long-term assets

     21       226       1,754  

Amortization of deferred loan fees

     1,906       536       254  

Gain on disposal of property, plant and equipment

     (75     (1,000     —   

Impairment of assets

     25,395       50,414       —   

Provision for estimated credit losses

     2,360       2,319       1,935  

Stock-based compensation

     2,016       4,412       6,138  

Deferred income taxes

     (1,351     1,452       (9,710

Changes in liabilities for uncertain tax positions or unrecognized tax benefits

     (201     (1,547     (508

Change in equity investment fair value

     437       2,356       359  

Lease obligations and non-cash lease expense, net

     (147     (37     256  

Unrealized foreign currency transaction (gains) losses

     (193     804       (581

Changes in assets and liabilities associated with operations, net of business combinations:

      

Decrease (increase) in receivables

     7,697       7,481       (20,278

Decrease (increase) in inventories

     6,287       35,178       (27,315

Decrease (increase) in income tax receivable/payable

     (9     (3,775     3,568  

(Increase) decrease in prepaid expenses and other assets

     (8,638     (687     1,269  

Increase (decrease) in accounts payable

     15,434       3,714       (2,287

Decrease in customer prepayments

     (19,582     (12,882     (45,079

(Decrease) increase in accrued program costs

     (17,384     1,775       7,244  

(Decrease) increase in accrued expenses and other payables

     (4,024     17,202       (5,066
  

 

 

   

 

 

   

 

 

 

Net cash (used in) provided by operating activities

     (21,191     3,923       (58,748
  

 

 

   

 

 

   

 

 

 

Cash flows from investing activities:

      

Capital expenditures

     (3,919     (7,279     (11,878

Proceeds from disposal of property, plant and equipment

     477       1,065       242  

Acquisitions of business and product line, net of cash acquired

     —        —        (5,195

Intangible assets

     (165     (409     (186
  

 

 

   

 

 

   

 

 

 

Net cash used in investing activities

     (3,607     (6,623     (17,017
  

 

 

   

 

 

   

 

 

 

Cash flows from financing activities:

      

Payments under line of credit agreement

     (223,465     (294,356     (172,500

Borrowings under line of credit agreement

     250,134       302,787       259,100  

Payment of deferred loan fees

     (3,389     (850     —   

Net receipt from the issuance of common stock under ESPP

     629       901       981  

Net (payment) receipt from the exercise of stock options

     (205     —        46  

Payment from common stock purchased for tax withholding

     —        (1,432     (1,967

Repurchase of common stock

     —        —        (15,539

Payment of cash dividends

     —        (2,510     (3,384
  

 

 

   

 

 

   

 

 

 

Net cash provided by financing activities

     23,704       4,540       66,737  
  

 

 

   

 

 

   

 

 

 

Net increase (decrease) in cash

     (1,094     1,840       (9,028

Effect of exchange rate changes on cash

     1,005       (742     116  

Cash at beginning of year

     12,514       11,416       20,328  
  

 

 

   

 

 

   

 

 

 

Cash at end of year

   $ 12,425     $ 12,514     $ 11,416  
  

 

 

   

 

 

   

 

 

 

 

8


AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

RECONCILIATION OF NET INCOME TO EBITDA

For the years ended December 31, 2025 and 2024

 

     For the years ended December 31,  
     2025     2024  

Net income

   $ (49,882   $ (126,340

Provision for income taxes

     2,679       5,882  

Interest expense, net

     18,470       16,243  

Depreciation and amortization

     18,763       22,548  

Stock compensation expense

     2,016       4,412  

Gain on sale of fixed assets

     (249     (1,000

Transformation costs

     7,187       20,162  

Other one-time charges

     3,907       60,799  

Goodwill and intangibles asset impairments

     25,300       36,395  

Product liability claims

     10,485       —   

Other adjustments

     531       —   
  

 

 

   

 

 

 

Adjusted EBITDA3

   $ 39,207     $ 39,101  
  

 

 

   

 

 

 

 

 
3 

Adjusted earnings before interest, taxes, depreciation, and amortization (Adjusted EBITDA) is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net (loss) income, operating (loss) income or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The items excluded from adjusted EBITDA are detailed in the reconciliation attached to this news release. Other companies (including the Company’s competitors) may define adjusted EBITDA differently.

 

9